NASDAQ:AQST

Aquestive Therapeutics (AQST) Stock Forecast, Price & News

$1.50

-0.08 (-5.06%)

(As of 09/25/2023 ET)

Compare

Today's Range: $1.48
▼
$1.61
50-Day Range: $1.50
▼
$2.24
52-Week Range: $0.72
▼
$2.69

Volume: 278,257 shs
Average Volume: 410,754 shs
Market Capitalization: $100.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Aquestive Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 300.0% Upside
$6.00 Price Target
Short Interest: Healthy
2.73% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.39
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.25) to ($0.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

693rd out of 962 stocks

Pharmaceutical Preparations Industry

312th out of 449 stocks

3.5

Analyst's Opinion

Consensus Rating
Aquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Aquestive Therapeutics has a forecasted upside of 300.0% from its current price of $1.50.
Amount of Analyst Coverage
Aquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.73% of the outstanding shares of Aquestive Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aquestive Therapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Aquestive Therapeutics has recently decreased by 7.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aquestive Therapeutics does not currently pay a dividend.
Dividend Growth
Aquestive Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AQST.

2.4

News and Social Media Coverage

News Sentiment
Aquestive Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Aquestive Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
MarketBeat Follows
9 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.39% of the stock of Aquestive Therapeutics is held by insiders.
Percentage Held by Institutions
Only 30.91% of the stock of Aquestive Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.25) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aquestive Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aquestive Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

AQST Price History

30 days | 90 days | 365 days | Advanced Chart

AQST Stock News Headlines

September 24, 2023 | americanbankingnews.com

Wedbush Reiterates "Outperform" Rating for Aquestive Therapeutics (NASDAQ:AQST)

September 24, 2023 | americanbankingnews.com

Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC Wainwright

September 26, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 23, 2023 | americanbankingnews.com

Aquestive Therapeutics' (AQST) "Market Outperform" Rating Reiterated at JMP Securities

September 22, 2023 | msn.com

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

September 21, 2023 | markets.businessinsider.com

Wedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)

September 21, 2023 | americanbankingnews.com

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Decline in Short Interest

September 20, 2023 | finance.yahoo.com

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

September 26, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 15, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Gains As Market Dips: What You Should Know

September 13, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know

September 11, 2023 | finance.yahoo.com

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

August 11, 2023 | finance.yahoo.com

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 11% loss last week hit both individual investors who own 60% as well as institutions

August 10, 2023 | finance.yahoo.com

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2023 Earnings Call Transcript

August 9, 2023 | markets.businessinsider.com

Wedbush Keeps Their Buy Rating on Aquestive Therapeutics (AQST)

August 8, 2023 | markets.businessinsider.com

Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities

August 7, 2023 | finance.yahoo.com

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023 | finance.yahoo.com

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023 | finance.yahoo.com

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

July 31, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Aquestive Therapeutics (AQST)

July 27, 2023 | finance.yahoo.com

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

July 26, 2023 | seekingalpha.com

Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem

July 25, 2023 | finance.yahoo.com

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

July 25, 2023 | finance.yahoo.com

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

July 21, 2023 | msn.com

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know

July 18, 2023 | msn.com

Aquestive Therapeutics (AQST) Outpaces Stock Market Gains: What You Should Know

July 14, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

See More Headlines

Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Company Calendar

Last Earnings: 8/07/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AQST
CUSIP: N/A
CIK: 1398733
Web: www.aquestive.com
Phone: (908) 941-1900
Fax: N/A
Employees: 130
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +300.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,410,000.00
Net Margins: -48.61%
Pretax Margin: -48.00%
Return on Equity: N/A
Return on Assets: -39.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.03
Quick Ratio: 0.88

Sales & Book Value

Annual Sales: $47.68 million
Price / Sales: 2.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.19) per share
Price / Book: -0.68

Miscellaneous

Outstanding Shares: 66,730,000
Free Float: 61,129,000
Market Cap: $100.10 million
Optionable: Not Optionable
Beta: 2.63

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Daniel Barber (Age 47)
CEO, Pres & Director
Comp: $925.35k

Mr. Alexander Mark Schobel (Age 64)
Chief Innovation & Technology Officer
Comp: $672.69k

Ms. Lori J. Braender BSBA (Age 67)
Esq., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Comp: $678.76k

Mr. A. Ernest Toth Jr. (Age 64)
Chief Financial Officer

Ms. Cassie Jung (Age 44)
Sr. VP of Operations

Mr. Peter E. Boyd (Age 57)
Sr. VP of IT, HR & Communications

Mr. Kenneth W. Marshall (Age 64)
Chief Commercial Officer

Dr. Gary H. Slatko M.D. (Age 66)
MBA, Chief Medical Officer

Dr. Stephen Wargacki (Age 45)
Sr. VP of R&D

Dr. Carl N. Kraus M.D. (Age 53)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AQST Stock - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings or view top-rated stocks.
What is Aquestive Therapeutics' stock price forecast for 2023?: 4 Wall Street research analysts have issued 12 month price targets for Aquestive Therapeutics' shares. Their AQST share price forecasts range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for AQST or view top-rated stocks among Wall Street analysts.
How have AQST shares performed in 2023?: Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of the year. Since then, AQST stock has increased by 66.3% and is now trading at $1.50.
View the best growth stocks for 2023 here.
Are investors shorting Aquestive Therapeutics?: Aquestive Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,820,000 shares, a drop of 7.1% from the August 15th total of 1,960,000 shares. Based on an average daily trading volume, of 374,400 shares, the days-to-cover ratio is presently 4.9 days.
View Aquestive Therapeutics' Short Interest.
When is Aquestive Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our AQST earnings forecast.
How were Aquestive Therapeutics' earnings last quarter?: Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm earned $13.24 million during the quarter, compared to analyst estimates of $10.76 million.
What guidance has Aquestive Therapeutics issued on next quarter's earnings?: Aquestive Therapeutics issued an update on its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $44.00 million-$48.00 million, compared to the consensus revenue estimate of $43.37 million.
What other stocks do shareholders of Aquestive Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?: (AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.
What is Aquestive Therapeutics' stock symbol?: Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."
Who are Aquestive Therapeutics' major shareholders?: Aquestive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.99%), Geode Capital Management LLC (0.67%), BlackRock Inc. (0.66%), Walleye Capital LLC (0.65%), Marshall Wace LLP (0.44%) and Acadian Asset Management LLC (0.29%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd.
View institutional ownership trends.
How do I buy shares of Aquestive Therapeutics?: Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aquestive Therapeutics' stock price today?: One share of AQST stock can currently be purchased for approximately $1.50.
How much money does Aquestive Therapeutics make?: Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $100.10 million and generates $47.68 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.
How many employees does Aquestive Therapeutics have?: The company employs 130 workers across the globe.
How can I contact Aquestive Therapeutics?: Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com.

This page (NASDAQ:AQST) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial